Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients

Autor: Astrid M. Newsum, Sebastiaan J. Hullegie, Bart J. A. Rijnders, F. N. Lauw, Jan van der Meer, Mark A. A. Claassen, Joop E. Arends, Dirk Posthouwer, Arne van Eeden, Peter P. Koopmans, Wouter F W Bierman, Eliane M. S. Leyten, Guido E.L. van den Berk, Clemens Richter
Přispěvatelé: RS: FHML non-thematic output, Med Microbiol, Infect Dis & Infect Prev, MUMC+: DA MMI Staf (9), Interne Geneeskunde, Infectious diseases, Other departments
Rok vydání: 2016
Předmět:
Male
CLEARANCE
medicine.disease_cause
THERAPY
RECOMMENDATIONS
Polyethylene Glycols
chemistry.chemical_compound
0302 clinical medicine
Pegylated interferon
Clinical endpoint
Prospective Studies
030212 general & internal medicine
POSITIVE PATIENTS
GENOTYPE 1
MEN
Hepatitis C
Middle Aged
Recombinant Proteins
Acute Disease
HCV
Drug Therapy
Combination
Female
TRIAL
030211 gastroenterology & hepatology
medicine.drug
Adult
medicine.medical_specialty
Proline
Hepatitis C virus
Acute hepatitis C
Alpha interferon
VIRUS-INFECTION
Interferon alpha-2
Antiviral Agents
03 medical and health sciences
Internal medicine
Boceprevir
Ribavirin
medicine
Humans
PEGYLATED INTERFERON-ALPHA-2B
Intention-to-treat analysis
Hepatology
business.industry
Interferon-alpha
HIV
medicine.disease
Treatment
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
chemistry
Immunology
Quality of Life
business
Zdroj: Journal of Hepatology, 64(4), 807-812. Elsevier Science
Journal of Hepatology, 64, 4, pp. 807-12
Journal of Hepatology, 64, 807-12
Journal of hepatology, 64(4), 807-812. Elsevier
Journal of Hepatology, 64(4), 807-812. ELSEVIER SCIENCE BV
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2015.12.004
Popis: Background & Aims: Acute hepatitis C virus infections (AHCV) are prevalent among HIV positive men having sex with men and generally treated with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) during 24 weeks. The addition of a protease inhibitor could shorten therapy without loss of efficacy.Methods: We performed an open-label, single arm study to investigate the efficacy and safety of a 12-week course of boceprevir, PegIFN and RBV for AHCV genotype 1 infections in 10 Dutch HIV treatment centers. The primary endpoint of the study was achievement of sustained virological response rate at week 12 (SVR12) in patients reaching a rapid viral response at week 4 (RVR4) and SVR12 in the intent to treat (ITT) entire study population was the most relevant secondary endpoint.Results: One hundred twenty-seven AHCV patients were screened in 16 months, of which 65 AHCV genotype 1 patients were included. After spontaneous clearance in six patients and withdrawal before treatment initiation in two, 57 started therapy within 26 weeks after infection. RVR4 rate was 72%. SVR12 rate was 100% in the RVR4 group. SVR12 rate in the ITT group was 86% and comparable to the SVR12 rate of 84% in 73 historical controls treated for 24 weeks with PegIFN and RBV in the same study centers.Conclusion: With the addition of boceprevir to PegIFN and RBV, treatment duration of AHCV genotype 1 can be reduced to 12 weeks without loss of efficacy. Given the high drug costs and limited availability of interferon-free regimens, boceprevir PegIFN and RBV can be a considered a valid treatment option for AHCV. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: